Work

A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.4_suppl.152

Authors: Benny Johnson, Jane V Thomas, Arvind Dasari, Kanwal Pratap Singh Raghav, Eduardo Vilar Sanchez, Bryan K. Kee, Cathy Eng, Christine Megerdichian Parseghian, Van K. Morris, Robert A. Wolff, Imad Shureiqi, Scott Kopetz, Michael J. Overman

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3004537286

Cites:

Cited by: 3

Related to: 10